Abstract at ASCO
Clinical utility of an international multidisciplinary virtual tumor board for fibrolamellar carcinoma.
Abstract at ASCO
Use of proton pump inhibitors (PPI) in glioblastoma (GBM) and relationship to overall survival in a national real-world evidence (RWE) database.
Abstract at ASCO
Leveraging real-world data from multiple institutions to assess the rate of bilateral mastectomy after cancer genetics evaluations with genetic counselors
Abstract at ASCO
Use of a nationwide, patient-powered observational platform to define the landscape of treatment, molecular profiling, and outcomes for fibrolamellar carcinoma
Poster at SNO
Real world clinical outcomes of patients with diffuse midline glioma in a longitudinal outcomes registry
Poster at SNO
Systems biology based therapeutic predictions with gbmSYGNAL and clinical correlates in the real world longitudinal outcomes registry XCELSIOR
Neuro-Oncology
Real-World Quality-of-Life and Health Utilities for Patients with CNS Cancers on the xCELSIOR Platform
Abstract at ASCO
Application of XCELSIOR, a nationwide real-world observational research protocol, to identify efficacious targeted therapy regimens in advanced pancreatic adenocarcinoma.
Journal of Clinical Oncology
Updated clinical outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523)
Melanoma Research
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma
Artificial Intelligence in Medicine
Virtual Trials: Causally-validated treatment effects efficiently learned from an observational brain cancer registry
Poster at ASCO GI
Cancer Commons’ Virtual Tumor Board program- a patient-centric advisory panel and Real-World Data registry.
Poster at SNO Meeting
XCELSIOR: A real-time, real-world learning platform for patients with advanced cancer.
Journal of Law, Medicine & Ethics
Is Cancer Solvable? Towards Efficient and Ethical Biomedical Science
JCO Precision Oncology
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma
BMC Bioinformatics
Prototyping a precision oncology 3.0 rapid learning platform
Clinical Pharmacology & Therapeutics